UA66758C2 - Pharmaceutical formulations comprising growth hormone, method for its production and method for treatment - Google Patents

Pharmaceutical formulations comprising growth hormone, method for its production and method for treatment

Info

Publication number
UA66758C2
UA66758C2 UA98105593A UA98105593A UA66758C2 UA 66758 C2 UA66758 C2 UA 66758C2 UA 98105593 A UA98105593 A UA 98105593A UA 98105593 A UA98105593 A UA 98105593A UA 66758 C2 UA66758 C2 UA 66758C2
Authority
UA
Ukraine
Prior art keywords
growth hormone
pharmaceutical formulations
treatment
production
amino acid
Prior art date
Application number
UA98105593A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of UA66758C2 publication Critical patent/UA66758C2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
UA98105593A 1996-04-24 1997-04-24 Pharmaceutical formulations comprising growth hormone, method for its production and method for treatment UA66758C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK49096 1996-04-24
PCT/DK1997/000184 WO1997039768A1 (en) 1996-04-24 1997-04-24 A pharmaceutical formulation containing growth hormone, an amino acid and a non-ionic detergent

Publications (1)

Publication Number Publication Date
UA66758C2 true UA66758C2 (en) 2004-06-15

Family

ID=8094154

Family Applications (1)

Application Number Title Priority Date Filing Date
UA98105593A UA66758C2 (en) 1996-04-24 1997-04-24 Pharmaceutical formulations comprising growth hormone, method for its production and method for treatment

Country Status (20)

Country Link
US (1) US20020077461A1 (cg-RX-API-DMAC10.html)
EP (2) EP1629832A1 (cg-RX-API-DMAC10.html)
JP (2) JP4176834B2 (cg-RX-API-DMAC10.html)
KR (1) KR20000010630A (cg-RX-API-DMAC10.html)
CN (1) CN1130223C (cg-RX-API-DMAC10.html)
AT (1) ATE309819T1 (cg-RX-API-DMAC10.html)
AU (1) AU733592B2 (cg-RX-API-DMAC10.html)
BR (1) BR9708858A (cg-RX-API-DMAC10.html)
CA (1) CA2252535C (cg-RX-API-DMAC10.html)
CZ (1) CZ298292B6 (cg-RX-API-DMAC10.html)
DE (1) DE69734653T2 (cg-RX-API-DMAC10.html)
DK (1) DK0904099T3 (cg-RX-API-DMAC10.html)
ES (1) ES2253774T3 (cg-RX-API-DMAC10.html)
HU (1) HU229868B1 (cg-RX-API-DMAC10.html)
IL (2) IL126463A0 (cg-RX-API-DMAC10.html)
NO (1) NO323360B1 (cg-RX-API-DMAC10.html)
PL (1) PL188222B1 (cg-RX-API-DMAC10.html)
RU (1) RU2236250C2 (cg-RX-API-DMAC10.html)
UA (1) UA66758C2 (cg-RX-API-DMAC10.html)
WO (1) WO1997039768A1 (cg-RX-API-DMAC10.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
AU1375199A (en) * 1997-11-12 1999-05-31 Alza Corporation Method for decreasing self-association of polypeptides
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
MXPA03001092A (es) 2000-08-07 2003-09-25 Nektar Therapeutics Al Corp Polvos de proteina de haz de 4 helices secados por rocio, inhalables, que tienen agregacion minimizada.
EP1603588A2 (en) * 2003-03-18 2005-12-14 Ares Trading S.A. Stabilisation of growth hormones in solution
EP1605922A4 (en) * 2003-03-24 2011-03-16 Biosphere Medical Inc TEMPORARY EMBOLIZATION USING REVERSIBLE THERMOSENSIVE POLYMERS WITH MOMENTARY ACTION
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US7700086B2 (en) * 2003-11-06 2010-04-20 Pluromed, Inc. Internal clamp for surgical procedures
BRPI0418115A (pt) * 2003-12-23 2007-04-17 Pharmacia Corp formulação lìquida estável de hormÈnio de crescimento
CN100574801C (zh) * 2004-04-07 2009-12-30 阿雷斯贸易股份有限公司 液体生长激素制剂
ZA200704926B (en) * 2004-12-22 2008-12-31 Ambrx Inc Modified human growth hormone
BRPI0519170A8 (pt) * 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
KR20070090023A (ko) * 2004-12-22 2007-09-04 암브룩스, 인코포레이티드 변형 인간 성장 호르몬
CA2620638A1 (en) 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
WO2007033427A1 (en) * 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation of peptides with basic amino acids
CN1939534B (zh) 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
ES2605022T3 (es) 2006-07-06 2017-03-10 Daewoong Co., Ltd. Una formulación líquida estable de la hormona del crecimiento humana
US9175061B2 (en) 2006-07-07 2015-11-03 Novo Nordisk Health Care Ag Protein conjugates and methods for their preparation
WO2008076819A2 (en) * 2006-12-18 2008-06-26 Altus Pharmaceuticals Inc. Human growth hormone formulations
AU2011208620B2 (en) 2010-01-22 2015-04-16 Novo Nordisk Health Care Ag Stable growth hormone compounds
CN103002918B (zh) 2010-01-22 2016-05-04 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
AU2011306653B2 (en) * 2010-09-21 2014-06-05 Ferring B.V. Improved process for production of recombinant human growth hormone
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
EP2981282B1 (en) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
HK1225976A1 (en) * 2013-09-27 2017-09-22 Hanmi Pharm. Co., Ltd. Sustained type human growth hormone preparation
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
HUE064656T2 (hu) 2016-03-28 2024-04-28 Incyte Corp Pirrolotriazin vegyületek mint TAM inhibitorok
US11932699B2 (en) 2017-09-07 2024-03-19 Jcr Pharmaceuticals Co., Ltd. Aqueous pharmaceutical composition
KR102739325B1 (ko) 2017-09-27 2024-12-09 인사이트 코포레이션 Tam 억제제로서 유용한 피롤로트리아진 유도체의 염
ES3031110T3 (en) 2018-06-29 2025-07-04 Incyte Corp Formulations of an axl/mer inhibitor
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
CN115634284B (zh) * 2022-10-31 2025-02-11 景泽生物医药(合肥)股份有限公司 一种促性腺激素冻干制剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003198A1 (en) * 1992-07-31 1994-02-17 Genentech, Inc. Human growth hormone aqueous formulation
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
DE10399015I1 (de) * 1991-12-20 2012-05-03 Novo Nordisk As Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält

Also Published As

Publication number Publication date
KR20000010630A (ko) 2000-02-25
BR9708858A (pt) 1999-08-03
CN1216472A (zh) 1999-05-12
CA2252535A1 (en) 1997-10-30
AU733592B2 (en) 2001-05-17
WO1997039768A1 (en) 1997-10-30
JP2000508665A (ja) 2000-07-11
NO984951L (no) 1998-10-23
ATE309819T1 (de) 2005-12-15
JP4176834B2 (ja) 2008-11-05
HU229868B1 (en) 2014-10-28
AU2634397A (en) 1997-11-12
NO984951D0 (no) 1998-10-23
CZ320798A3 (cs) 1999-03-17
DE69734653D1 (de) 2005-12-22
PL329386A1 (en) 1999-03-29
HUP9902476A3 (en) 2000-12-28
PL188222B1 (pl) 2004-12-31
ES2253774T3 (es) 2006-06-01
IL126463A0 (en) 1999-08-17
EP1629832A1 (en) 2006-03-01
RU2236250C2 (ru) 2004-09-20
CN1130223C (zh) 2003-12-10
US20020077461A1 (en) 2002-06-20
CA2252535C (en) 2009-06-23
HUP9902476A2 (hu) 2000-11-28
IL126463A (en) 2007-06-17
EP0904099A1 (en) 1999-03-31
DK0904099T3 (da) 2006-03-06
JP2008231124A (ja) 2008-10-02
DE69734653T2 (de) 2006-08-10
CZ298292B6 (cs) 2007-08-15
EP0904099B1 (en) 2005-11-16
NO323360B1 (no) 2007-04-10

Similar Documents

Publication Publication Date Title
UA66758C2 (en) Pharmaceutical formulations comprising growth hormone, method for its production and method for treatment
MD1699F2 (ro) Compoziţie apoasă a hormonului somatotrop uman şi procedeu de prevenire a denaturării ei
WO1999012561A3 (en) FRACTURE HEALING USING PTHrP ANALOGS
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
WO2002048183A3 (en) Compositions of peptide crystals
EP1025840A3 (en) Oral drug compositions and methods
AU2002223684A1 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
WO2002043750A8 (en) Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
DE60000288D1 (de) Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
WO2003047500A3 (en) Vaccine and method for treatment of motor neurone diseases
SE9801495D0 (sv) Protein formulationa
WO2003028623A3 (en) Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucuous membranes
EE9900428A (et) Köhavastased ravimkoostised
CA2303395A1 (en) Treatment of obesity
HUP0003840A2 (hu) Szabályozott hatóanyagleadású gyógyászati készítmények
WO2002051379A3 (en) Thixotropic nasal spray
GB2328872B (en) Method for preparing pharmaceutical formulations
CA2429793A1 (en) Interferon therapeutic effect enhancer
IL145722A0 (en) Pharmaceutical composition comprising growth hormone and interferon
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
YU44292A (sh) Superaktivni analozi faktora oslobadjanja hormona rasta
CA2237643A1 (en) Therapeutic agent for acute hepatic failure
PT1448220E (pt) Agente farmacêutico contendo uma substância activa antiflogística e hidrolisado de lactalbumina e respectiva utilização